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Abstract
Background
To identify prognostic factors and define the optimal management of patients with supraten-
torial primitive neuroectodermal tumors (sPNETs), we investigated treatment outcomes and
explored the prognostic value of specific molecular markers.
Methods
A total of 47 consecutive patients with pathologically confirmed sPNETs between May 1985
and June 2012 were included. Immunohistochemical analysis of LIN28, OLIG2, and Rad51
expression was performed and correlated with clinical outcome.
Results
With a median follow-up of 70 months, 5-year overall survival (OS) and progression-free
survival (PFS) was 55.5% and 40%, respectively, for all patients. Age, surgical extent, and
radiotherapy were significant prognostic factors for OS and PFS. Patients who received ini-
tially planned multimodal treatment without interruption (i.e., radiotherapy and surgery
(subtotal resection), with or without chemotherapy) showed significantly higher 5-year OS
(71.2%) and PFS (63.1%). In 29 patients with available tumor specimens, tumors with high
expression of either LIN28 or OLIG2 or elevated level of Rad51 were significantly associ-
ated with poorer prognosis.
Conclusions
We found that multimodal treatment improved outcomes for sPNET patients, especially
when radiotherapy andsubtotal resection were part of the treatment regimen.
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Furthermore, we confirmed the prognostic significance of LIN28 and OLIG2 and revealed
the potential role of Rad51 in sPNETs.
Introduction
Primitive neuroectodermal tumors (PNETs) are the most frequent type of malignant pediatric
brain tumors, which primarily consist of undifferentiated round neuroepithelial cells. PNETs
include central nervous system (CNS) PNETs (also called supratentorial PNETs or sPNETs).
Although sPNETs are histologically indistinguishable from medulloblastoma, multiple studies
have identified different molecular characteristics between the two types of tumors, suggesting
differences in their clinical prognosis [1, 2].
sPNETs are associated with poor prognosis, with a 5-year event-free survival rate of 30–60%
depending on treatment modality. Certain factors, including young age, tumor dissemination,
no radiotherapy, and no grossly total resection, are related to poorer prognosis, emphasizing
the importance of multimodal treatment or tailored therapeutic strategies for each patient [3–
5]. The standard treatment for sPNETs has typically been intensive, consisting of major surgi-
cal resection when feasible, followed by radiotherapy and chemotherapy [6–10].
Recently, molecular profiling is important for prognosis and selection of appropriate modal-
ity. However, the molecular composition of most sPNETs is unknown, and the prognostic
impact of various pathologic and genetic factors has not been thoroughly investigated. Three
molecular subgroups of sPNETs have been found to exhibit differential expression of cell-line-
age markers LIN28 and OLIG2, and to be related to distinct demographic features [11, 12]. We
tried to find other prognostic markers in sPNET. There are other molecular markers affecting
resistance against radiation therapy and local failure, and Rad51 is one of these key proteins.
Expression of Rad51, which plays a central role in the repair of DNA double-strand breaks, has
been recently examined in many types of tumors [13] but not sPNETs. It is generally suggested
that Rad51 overexpression increases cellular resistance to radiation and some chemotherapeu-
tic drugs [14]. Rad51 overexpression is associated with poor prognosis for many cancers [15–
18], with only two studies showing the opposite relationship [19, 20]. Thus, we suggested that
this molecular marker could not only be used to predict prognosis but may also serve as poten-
tial therapeutic targets for sPNETs.
At our institution, patients with sPNETs have received multimodal treatment including sur-
gery, radiotherapy, and chemotherapy depending on each patient’s risk factors and disease sta-
tus. To identify prognostic factors and define optimal management of sPNET patients, we first
investigated treatment outcomes at our institution. Second, we analyzed levels of LIN28,
OLIG2, and Rad51 expression and correlated these expression levels with patient survival.
Materials and Methods
Patient characteristics
Fifty-four consecutive patients with pathologically confirmed sPNETs who were treated
between May 1985 and June 2012 were retrospectively reviewed. Seven patients were excluded
because of insufficient treatment information, follow-up loss, or uncertain pathology. There-
fore, a total of 47 patients were included in the analysis. All patients were pathologically classi-
fied as sPNETs according to the revised WHO classification 2007. Patient characteristics are
summarized in Table 1. The median follow-up duration was 70 months (range, 7 months-28
years), and the average follow-up duration was 59 months. Patients with a follow-up duration
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shorter than 1 year had all died, even at 7 months after diagnosis. This study was approved by
Institutional review board (IRB) of Yonsei University Health System. The patient records/
information was anonymized and de-identified prior to analysis, and informed consent was
not obtained from each participants.
Treatment
Various treatment characteristics were analyzed, including treatment modality, extent of resec-
tion, use of radiotherapy, and use of chemotherapy. Surgical extent was classified as grossly
total resection (GTR), subtotal resection (STR), or partial resection (PR). Subtotal and partial
resection was defined as resection of a gross tumor by more or less than 90%, respectively. Sur-
gical extent was determined according to the surgeon’s operation record and MRI scans con-
ducted within 48 hours after surgery.
At our institution, sPNET patients are generally treated with the combined use of surgery
and radiotherapy. Twenty-two patients received surgery, radiotherapy, and chemotherapy; 9
patients received surgery and radiotherapy; 3 patients received surgery and chemotherapy; 5
patients received surgery only; and 8 patients were treated without surgery (i.e., chemotherapy
and radiotherapy, chemotherapy alone, or biopsy alone). Among the 39 patients who under-
went surgery, GTR was performed in 14 patients (36%), STR in 19 patients (49%), and PR in 6
patients (15%). Enhancement in T1-weighted postoperative magnetic resonance imaging
(MRI) images was considered residual tumor. Treatment characteristics are summarized in
Fig 1.
Chemotherapy is also given concomitantly depending on the patient’s condition and tumor
characteristics. Chemotherapy was performed in 29 out of 47 patients. Diverse chemotherapy
Table 1. Patient characteristics.
Variables No. %
Sex
M 19 40
F 28 60
Age
Median (months) 140
Range (months) 1–828
< 3 years 7 15
 3 years 40 85
Initial KPS
< 80 22 47
 80 25 53
Tumor location
Pineal gland 14 30
Non-pineal gland 33 70
Multiplicity
Yes 3 6
No 44 94
Metastasis
Yes 12 26
No 35 74
Abbreviations: KPS, Karnofsky performance status
doi:10.1371/journal.pone.0153443.t001
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regimens were used according to patient age and disease status at the time of diagnosis for a
long time period in our study. The most commonly used chemotherapy regimens were Cis-
platin, Etoposide, Cyclophosphamide/Ifosfamide, and Vincristine.
Radiotherapy
Radiotherapy regimens consisted predominantly of craniospinal irradiation (CSI) and the
application of external beam radiotherapy to the tumor bed. The use and timing of radiother-
apy was determined by a radiation oncologist and largely based on the patient’s functional sta-
tus, age, and physician preference. The choice between focal radiotherapy with and without
CSI was influenced by the age of the patient; those younger than 3 years of age were more likely
to receive focal radiotherapy without CSI.
Among the 34 patients who received radiotherapy, 31 were treated with CSI at a median
dose of 36 Gy (range, 23.4–39 Gy) and focal radiotherapy at doses ranging from 14–36 Gy.
One patient received whole-brain radiotherapy with focal boost radiotherapy (total 45 Gy).
The median dose of total radiation was 54 Gy (range, 40.2–60 Gy). Four patients were treated
with CSI at a dose of less than 30 Gy. Two young patients received CSI at a dose 23.4 Gy and
additional focal radiotherapy for a total dose of 54 Gy and 59.4 Gy, respectively. Another
patient received CSI at a dose of 24 Gy and additional focal radiotherapy for a total dose of 40.2
Gy (this patient was initially diagnosed with germinoma and treated accordingly due to insuffi-
cient biopsied material, tumor marker information, and similar features in imaging studies).
Fig 1. Treatment flowchart for 47 patients with sPNET.Op, operation; RT, radiotherapy; CTx, chemotherapy; Bx, biopsy; GTR, grossly total resection;
STR, subtotal resection; PR, partial resection.
doi:10.1371/journal.pone.0153443.g001
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Finally, another patient received CSI at a dose of 23.4 Gy and additional focal radiotherapy for
a total dose of 59.4 Gy.
Immunohistochemistry and assessment of LIN28A, OLIG2, and Rad51
Of the 47 patients, tissue samples were available for 29 patients. All of these patients showed
positive INI-1 staining (clone BAF47, BD Bioscience, San Jose, CA, USA), ruling out the possi-
bility of atypical teratoid/rhabdoid tumor. Archived formalin-fixed, paraffin-embedded tissue
slides underwent immunohistochemical staining for LIN28A (clone A177, Cell Signaling, Dan-
vers, MA, USA, 1:100 dilution), OLIG2 (polyclonal, R&D Systems, Minneapolis, MN, USA,
1:200 dilution), and RAD51 (clone H-92, Santa Cruz, Santa Cruz, CA, USA, 1:25 dilution) fol-
lowing protocols for the Ventana Discovery XT automatic platform (Ventana Medical System,
Tucson, AZ, USA). Evaluation of cytoplasmic LIN28 and nuclear OLIG2 expression was per-
formed by two pathologists (SH Kim and J Choi) according to the methods of Picard et al.[11].
High LIN28 and low OLIG2 expression was classified as Group 1, high OLIG2 and low LIN28
expression was classified as Group 2, and low or absent LIN28 and OLIG2 expression was clas-
sified as Group 3 (Fig 2A).
Evaluation of nuclear RAD51 immunohistochemistry was performed according to the
methods of Qiao et al.[17]. We calculated a positive-cell index (PCI) defined as the proportion
of positively stained tumor cells. At least 200 tumor cells were counted for each specimen.
Using this method, a PCI of 10% was identified as the optical cutoff; samples showing a
PCI<10% were considered negative, whereas those showing a PCI>10% were considered posi-
tive (Fig 2B).
Statistical analysis
The Kaplan-Meier method was used to calculate the rates of overall survival (OS) and progres-
sion-free survival (PFS). OS was calculated from the date of the initial diagnosis to the date of
death due to any cause, or the date of the last follow-up. PFS was calculated from date of the
initial diagnosis to the date of recurrence or progression, or the date of the last follow-up date
for patients who did not experience these events. Differences in OS and PFS between groups
were estimated using log-rank tests and Cox regression. A two-tailed p-value<0.05 was consid-
ered statistically significant. All statistical analyses were carried out using SPSS version 20.0
(SPSS Inc., Chicago, IL, USA).
Results
Survival and prognostic factors
We first analyzed disease progression and survival rates depending on treatment modality
(Fig 1). Survival rate was the highest in the surgery, radiotherapy, and chemotherapy group.
Eight patients (36%) experienced disease progression, and seven of these patients died (one
patient experienced disease progression but lived after salvage treatment). The death of the two
patients without disease progression/recurrence was due to unknown causes and subdural
hemorrhage, respectively. In the surgery and radiotherapy group, four patients (44%) experi-
enced disease progression and died. In the surgery and chemotherapy group, disease progres-
sion was confirmed for only one patient (33%), but all three patients died at 2.6 months, 3.9
months, and 22.7 months, respectively, due to sepsis after chemotherapy. In the surgery only
group, four patients (80%) experienced disease progression, and three of these patients died.
The non-surviving patient without disease progression had a persistent tumor and died after
33 days of semicoma status after surgery. In the chemotherapy and radiotherapy group, two
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Fig 2. (a) Group 1, 2, and 3 classifications were based on immunohistochemical staining of LIN28 and OLIG2 (magnification: 400×). (b) All tissue specimens
showed positive nuclear INI-1 staining (A, magnification: 100×). Tissue specimens were positive (B, magnification: 400×) or negative (C, magnification: 400×)
for nuclear RAD51staining.
doi:10.1371/journal.pone.0153443.g002
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patients (67%) experienced disease progression and died. The surviving patient with no disease
progression was 7 years old when she was diagnosed with PNET of the pineal gland. She
received 36 Gy of CSI, 19.8 Gy of additional local boost, and chemotherapy. The one patient in
the chemotherapy only group (100%) died of the disease after 6.74 months. In the biopsy only
group, all four patients showed disease progression, and three of them died.
Considering all patients, the 3- and 5-year OS were 55.5% and 49.4%, and the 3- and 5-year
PFS were 43% and 40% (Fig 3A). Patients who initially planned to receive multimodal treat-
ment without interruption (radiotherapy and surgery (STR), with or without chemotherapy)
showed significantly higher 3- and 5-year OS and PFS than patients without multimodal treat-
ment (OS: 77.1% and 71.2% vs. 33.2% and 27.7%, p = 0.001; PFS: 68.8% and 63.1% vs. 17.4%
and 17.4%, p<0.001, respectively; Fig 3B and 3C). Multimodal treatment was also significantly
Fig 3. (a) OS and PFS for all patients (n = 47). (b) OS depending on inclusion of multimodal treatment. (c) PFS depending on inclusion of multimodal
treatment. Multimodal treatment consisted of radiotherapy and surgery (subtotal resection), with or without chemotherapy (with multimodal treatment,
n = 24; without multimodal treatment, n = 23).
doi:10.1371/journal.pone.0153443.g003
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associated with better 3- and 5-year OS and PFS (OS: 84.1% and 77.1% vs. 40.5% and 33.8%,
p = 0.006; PFS: 73.9% and 67.2% vs. 21.1% and 21.1%, p = 0.001) among patients who were
older than 3 years of age.
In univariate analysis, age (3 years), surgical extent (STR), and radiotherapy were signif-
icant prognostic factors for OS (p = 0.009, 0.014, and<0.001) and PFS (p = 0.03, 0.009, and
<0.001). In multivariate analysis, radiotherapy was an independent prognostic factor for OS
(p = 0.001) and PFS (p<0.001) (Table 2).
Patterns of treatment failure
Disease progression was observed in 23 patients (48.9%), with eight showing persistent disease
and 14 experiencing recurrence after a response to treatment. The most common site of disease
recurrence was the primary tumor site (93%). Twenty-one patients showed disease progression
in the local CNS, whereas only one patient showed disease progression in the distant CNS. Pat-
terns of treatment failure were not significantly related to radiotherapy dose or mode of
treatment.
Patients less than 3 years old
The seven patients who were younger than 3 years old showed much worse prognosis than
those who were older than 3 years old. Three patients received multimodal treatment including
radical surgery, radiotherapy including CSI, and chemotherapy. In our institution, we
attempted radiotherapy after resection and/or chemotherapy once the patient was older than 3
years, as long as the patient was tolerable to radiotherapy (2: biopsy only, 1: resection only, 1:
chemotherapy only). The 3-year OS and PFS of the three patients who received multimodal
treatment were higher than those of the patients who did not receive multimodal treatment,
but these differences were not statistically significant (OS: 84.1% vs. 33.3%, p = 0.069; PFS:
73.9% vs. 33.3%; p = 0.123).
Molecular markers
Next, we examined tumor biopsies from patients (n = 29) using immunohistochemistry to
investigate the patterns and intensities of LIN28, OLIG2, and Rad51 expression.
LIN28 and OLIG2. We classified sPNET patients into three molecular subgroups based
on differential expression of tumor cell lineage markers LIN28 and OLIG2 according to the
methods of Picard et al.[11] Two patients (7%) belonged to Group 1, 7 patients (24%) belonged
to Group 2, and 20 patients (69%) belonged to Group 3. We found no differences in sex, age, or
treatment modality between the three molecular subgroups.
Patients in Group 1 had the poorest OS (median survival: 7.66 months for Group 1, 14.4
months for Group 2, and 29.58 months for Group 3) and PFS (median survival: 4.35 months
for Group 1, 8.57 months for Group 2, and 25.83 months for Group 3; Fig 4A and 4B). Univari-
ate analysis showed that PFS was significantly poorer for Group 1 + 2 than for Group 3
(p = 0.013) and significantly poorer for Group 1 than for Group 2 + 3 (p = 0.001). A similar
pattern of differences between groups was observed for OS, but these differences were not sta-
tistically significant (Group 1+2 vs. 3, p = 0.084; Group 1 vs. 2+3, p = 0.231). We also found dif-
ferences between groups in the incidence of tumor metastases at initial diagnosis. Patients in
Group 3 had higher incidence of disseminated disease at diagnosis (5/20, 25%) than the other
groups (Group 1: 0/2, 0%; Group 2: 1/7, 17%), but it was not statistically significant.
Rad51. We found an elevation of Rad51 expression in 45% of tumor specimen (13
patients). No significant differences were found between patients with elevated or low/absent
Rad expression with regard to age, surgery extent, or radiotherapy.
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Univariate analysis showed that patients with elevated Rad51 levels exhibited significantly
worse 5-year OS and PFS than patients with low or absent Rad51 (OS: 15.2% vs. 62.5%,
p = 0.050; PFS: 0% vs. 56.3%, p = 0.022). Disease progression was found in 69% of patients in
the Rad (+) group and 38% of patients in the Rad (-) group (Fig 4C and 4D).
Table 2. Prognostic factors for OS and PFS as shown by univariate andmultivariate analyses.
OS PFS
Univariate Multivariate Univariate Multivariate
Variable 5-year (%) P value HR (95% CI) P value 5-year (%) P value HR (95% CI) P value
Sex
Male 54 0.70 41 0.80
Female 47 42
Location
Pineal gland 55 0.80 49 0.80
Others 46 36
Age
< 3yr 14 0.01 0.35 (0.13–0.95) 0.04 14 0.03 0.48 (0.18–1.25) 0.13
 3yr 56 0.09 (0.01–0.60)* 0.01* 40
KPS
< 80 37 0.09 32 0.06 2.81 (1.04–7.62)* 0.04*
 80 59 47
Multiplicity
Yes 66 0.90 33 0.70
No 49 41
Metastasis
Yes 52 0.60 42 0.80
No 48 41
STR
Yes 61 0.01 0.58 (0.23–1.46) 0.24 52 0.01 0.78 (0.32–1.90) 0.58
No 22 0.13 (0.04–0.43)* 0.00* 14
RT
Yes 65 <0.001 0.21 (0.08–0.52) 0.00 56 < 0.001 0.14 (0.06–0.37) < 0.001
No 10 0 0.11 (0.04–0.37)* < 0.001*
CTx
Yes 50 0.60 43 0.20
No 49 35
Rad 51
Positive 15 0.05* 0 0.02* 5.73 (1.65–19.89)* 0.00*
Negative 63 56
LIN28, OLIG2 group Group 1+2 vs. 3 Group 1+2 vs. 3
Primitive neural (group 1) 0 0.08* 0.19 (0.06–0.65)* 0.01* 0 0.01* 0.17 (0.05–0.52)* 0.00*
Oligoneural (group 2) 43 29
Mesenchymial (group 3) 49 41
Abbreviations: OS, overall survival; PFS, progression-free survival; KPS, Karnofsky performance status; STR, subtotal resection; RT, radiotherapy; CTx,
chemotherapy; HR, hazard ratio; CI, conﬁdence interval
*: Results from subgroup analysis including 29 patients with available tumor biopsies.
doi:10.1371/journal.pone.0153443.t002
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When possible, prognostic parameters (i.e., age 3 years old, surgical extent, use of radio-
therapy, expression of molecular markers, and Karnofsky Performance Score (KPS)) were
included in multivariate analysis. LIN28/OLIG2 expression, STR, and age were significant
prognostic factors for OS, and LIN28/OLIG2 expression, Rad51 expression, use of radiother-
apy, and KPS were significant prognostic factors for PFS (Table 2).
Discussion
We found that multimodal treatment improves outcomes for patients with sPNETs, especially
when radiotherapy including CSI and at least subtotal surgical resection were part of the treat-
ment regimen. Because local disease progression was the primary recurrence pattern, local con-
trol should be preferred to improve survival, with a sufficient extent of surgery and proper total
dose of radiotherapy for each patient. These findings are consistent with many previously pub-
lished results [3–7] but are in contrast to a recent retrospective analysis that suggests that OS
Fig 4. (a) OS depending on LIN28/OLIG2 expression level. (b) PFS depending on LIN28/OLIG2 expression level (Group 1: n = 2, Group 2: n = 7, Group 3:
n = 20). (c) OS depending on Rad51 expression level ((+): n = 13, (-): n = 16)). (d) PFS depending on Rad expression level.
doi:10.1371/journal.pone.0153443.g004
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does not correlate with the extent of resection [21]. Other studies show that factors including
the age of less than 3 years, metastasis, tumor necrosis, and tumor dissemination are associated
with poor prognosis, especially for childhood cases of sPNETs. Similarly, we found that age,
surgical extent, and radiotherapy were significant prognostic factors in both univariate and
multivariate analyses. In particular, the inclusion of radiotherapy in the treatment regimen was
the most powerful prognostic factor. Additionally, we also found that specific molecular mark-
ers are significant prognostic factors for sPNETs.
Even with good prognostic factors and aggressive treatments, sPNET patients have a poor
prognosis, with previous studies reporting a median survival time ranging from only 8 to 23
months. For children, the reported 3- and 5-year survival rates are 34–57% and 18–38%,
respectively [3–7, 10, 22]. There have been promising results utilizing myeloablative chemo-
therapy and autologous hematopoietic cell rescue (without radiotherapy) in young patients
[23–25]. Survival rates for adults, however, are worse than those for children. Gandhi et al.
reports a median survival time of 16 months in adults with sPNETs, with 1-, 2-, and 5-year sur-
vival rates of 55.3%, 35.0%, and 16.5%, respectively [26]. At our institution, the 3- and 5-year
OS were 55.5% and 49.4% considering all patients, which are higher rates than those reported
by other studies. Furthermore, we found that multimodal treatment without interruption was
associated with particularly high 3- and 5-year OS of 73.1% and 67.9%. This multimodal treat-
ment, which includes maximum surgical resection and radiotherapy, also improved survival
even in patients under 3 years of age, which was the group with a very poor prognosis (i.e.,
3-year OS and PFS of 33.3% and 33.3%, respectively).
Previous studies have identified several prognostic biomarkers for diverse disease entities,
including sPNETs, using immunohistochemical and genetic assays. Rad51 is one of these
important molecular markers that has frequently been studied in diverse diseases but not in
sPNETs. Rad51 plays a crucial role in the homologous recombination repair pathway by facili-
tating strand transfer between broken sequences and their undamaged homologues. Its expres-
sion is tightly controlled in normal cells, as inappropriate recombination can lead to genomic
instability, but its overexpression is observed in the majority of human tumor cells. Several
studies demonstrate that Rad51 is not only involved in the progression of carcinogenesis, but
also affects resistance to anticancer treatments, particularly by influencing the amount of radia-
tion-induced cell death [27, 28]. Rad51 overexpression correlates with poor prognosis in many
cancers [15–18], but its relationship with CNS tumors, including sPNETs, has not yet been
thoroughly explored. In one study of glioblastoma patients, Welsh et al. unexpectedly reported
that increased Rad51 expression at diagnosis is correlated with improved survival, although the
exact pathway is not well understood [19]. Here, for the first time, we analyzed the relationship
between elevated Rad51 expression and the survival of sPNET patients. Similar to previous
studies of other diseases, we found that elevated Rad51 expression was significantly associated
with worse survival rates for sPNET patients, supporting the hypothesis that Rad51 might pro-
mote radiation resistance.
The molecular composition of sPNETs is largely unknown. To improve treatment out-
comes, the understanding of molecular features and the identification of appropriate therapeu-
tic targets is important. In recent studies, a distinctly aggressive molecular subgroup that
showed frequent amplification of chromosome 19q13 miRNA cluster (C19MC) was identified
in sPNETs [29, 30]. Picard et al. identified three distinct molecular subgroups of sPNETs using
cell-lineage markers LIN28 and OLIG2 [11]. Primitive neural Group 1 tumors, with frequent
C19MC amplification and high LIN28 expression, are distinctly aggressive, whereas mesenchy-
mal Group 3 tumors, with low LIN28 and OLIG2 expression, are associated with a high inci-
dence of metastasis. In the present study, we reconfirmed that LIN28 and OLIG2 are
promising diagnostic and prognostic molecular markers, even with a small number of patients.
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New treatment strategies or more aggressive treatments are warranted for patients with Group
1 tumors, as these patients show the worst survival rates even with multimodal treatment. Such
molecular markers will help predict prognosis and enable tailored treatments for each sub-
group of patients.
Nonetheless, this study has several limitations that should be noted. First, due to the rarity
of sPNETs, our sample size was relatively small. Second, this is a retrospective review spanning
a long time period, during which major advances in surgical technique, radiation delivery, and
chemotherapeutic agents have occurred. However, we selected only those patients who
received surgery and radiotherapy at our institution with exact treatment information to mini-
mize bias in this analysis. Third, due to the variability in the definition of PNET pathology,
patients with heterogeneous prognosis might have been included in our analysis. Even with
these kinds of heterogeneity, however, our study showed overall excellent survival outcomes of
multimodal treatment and identified valuable prognostic molecular markers.
As already known, we observed a positive trend toward improved OS with more extensive
resection and radiotherapy including CSI. Thus, sPNETs should be treated aggressively after
multidisciplinary discussion. The study of molecular markers will help to classify CNS PNETs
and to identify high-risk subgroups that need more aggressive treatments tailored to their spe-
cific biological profiles. We confirmed the role of LIN28 and OLIG2, which were previously
proposed as prognostic molecular markers for sPNETs, and also discovered the role of Rad51
in sPNET prognosis. Prospective studies or larger cohort studies will help unravel the relation-
ship between these molecular markers and clinical outcomes and determine ideal therapeutic
strategies. In summary, we examined multiple prognostic molecular markers and their clinical
meaning, and our study is the first to identify the role and prognostic importance of Rad51 in
sPNETs.
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